[Skip to Navigation]
Sign In
Views 2,326
Citations 0
Editorial
March 25, 2021

JAMA Oncology—The Year in Review, 2020

Author Affiliations
  • 1Editor, JAMA Oncology
  • 2Fred Hutchinson Cancer Research Center, University of Washington, Seattle
JAMA Oncol. 2021;7(5):683-684. doi:10.1001/jamaoncol.2021.0094

2020 has been an unprecedented year, not only for the world but also for JAMA Oncology. The coronavirus disease 2019 (COVID-19) pandemic dominated both the news and the medical literature. JAMA Oncology received more than 350 manuscripts related to the COVID-19 pandemic in 2020, including one of the first reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in patients with cancer from Wuhan province, China, which was published on March 25, 2020 (Table).1-6

Table.  JAMA Oncology Statistics for 2020
JAMA Oncology Statistics for 2020

I thank our authors, reviewers, and readers for the significant contributions made to the journal this past year, especially surrounding the pandemic. The editorial board, our JAMA Oncology editors, and I are honored to have the opportunity to serve the oncology community by offering original, innovative, and timely scientific content that has a direct impact on researchers, clinicians, and the patients we serve. Most importantly, we rapidly evaluated and published COVID-19–related articles to provide needed information for decision-making concerning the infection and its implications in patients with cancer and cancer treatment changes during the pandemic. The journal’s impact factor of 24.8 places it as one of the highest-ranking oncology journals.

Evaluating and selecting the best manuscripts for publication in the journal was rewarding but challenging. JAMA Oncology received a total of 3777 manuscript submissions in 2020. These submissions included 2967 Original Investigations and 115 Reviews. In 2020, we published 412 total articles, including 102 Original Investigations, 23 Brief Reports, 39 Research Letters, 12 Reviews, 46 Viewpoints, and 1 Special Communication. I would like to thank our authors for choosing to submit their articles to JAMA Oncology. The quality of their published articles is reflected in the more than 4.6 million views they received in 2020.

In 2020, the overall acceptance rate was 11%. The acceptance rate for Original Investigations was 6%. We accepted 15% of Review articles, 11.6% of submitted Research Letters, 19% of Viewpoints, and 11.6% of Clinical Challenges. JAMA Oncology is indexed in PubMed/MEDLINE, Web of Science, Scopus, and other databases. More detailed statistics about the journal’s content are displayed in the Table.

We are also very grateful to our global consortium of peer reviewers who contributed to the journal this year. I am pleased to acknowledge their contribution to JAMA Oncology by publishing the names of the 826 experts who completed a manuscript review in 2020.7 This group of renowned laboratory, clinical, quantitative, and statistical scientists rapidly provided comprehensive reviews of the submitted manuscripts. The median time from the receipt of a manuscript to the first decision with peer review was 41 days in 2020. The ability to rapidly review and return a decision on our submissions ensures that important findings are available to the oncology community as quickly as possible. We would not be able to provide this service without our expert peer reviewers and their commitment to providing prompt and high-quality reviews for the journal. We thank you!

Finally, I thank our readers. We provided the journal’s electronic table of contents of newly published material each week by email to more than 62 000 readers in 2020. If you currently do not receive JAMA Oncology’s electronic table of contents by email, you can sign up at http://www.jamaoncology.com/. We are proud to continue offering the most innovative, provocative, and timely research for scientists, clinicians, and trainees in the field of oncology worldwide. I encourage readers to stay involved with the journal by submitting Letters to the Editor and online comments and offering recommendations for new topics that you would like to see covered in future issues. Your suggestions make this interdisciplinary oncology journal dynamic and current.

We have truly enjoyed being involved in JAMA Oncology’s continued success this year, and we look forward to the year ahead. We could not have done it without you. I invite all of our readers to follow us on Twitter @JAMAOnc or friend JAMA Oncology on Facebook along with a community of more than 58 000 people. We will keep you up to date on the most important discoveries influencing cancer care.

Back to top
Article Information

Corresponding Author: Mary L. (Nora) Disis, MD, Fred Hutchinson Cancer Research Center, University of Washington, 850 Republican St, Brotman 221, Box 358050, Seattle, WA 98195-8050 (ndisis@uw.edu).

Published Online: March 25, 2021. doi:10.1001/jamaoncol.2021.0094

Conflict of Interest Disclosures: None reported.

References
1.
Lee  A, Shah  K, Chino  F.  Assessment of parking fees at National Cancer Institute–designated cancer treatment centers.   JAMA Oncol. 2020;6(8):1295-1297. doi:10.1001/jamaoncol.2020.1475PubMedGoogle ScholarCrossref
2.
Mackintosh  C, Yuan  C, Ou  F-S,  et al.  Association of coffee intake with survival in patients with advanced or metastatic colorectal cancer.   JAMA Oncol. 2020;6(11):1713-1721. doi:10.1001/jamaoncol.2020.3938PubMedGoogle ScholarCrossref
3.
Gilchrist  SC, Howard  VJ, Akinyemiju  T,  et al.  Association of sedentary behavior with cancer mortality in middle-aged and older US adults.   JAMA Oncol. 2020;6(8):1210-1217. doi:10.1001/jamaoncol.2020.2045PubMedGoogle ScholarCrossref
4.
Yu  J, Ouyang  W, Chua  MLK, Xie  C.  SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China.   JAMA Oncol. 2020;6(7):1108-1110. doi:10.1001/jamaoncol.2020.0980PubMedGoogle ScholarCrossref
5.
Sledge  GW  Jr, Toi  M, Neven  P,  et al.  The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial.   JAMA Oncol. 2020;6(1):116-124. doi:10.1001/jamaoncol.2019.4782PubMedGoogle ScholarCrossref
6.
Phillips  R, Shi  WY, Deek  M,  et al.  Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial.   JAMA Oncol. 2020;6(5):650-659. doi:10.1001/jamaoncol.2020.0147PubMedGoogle ScholarCrossref
7.
 JAMA Oncology peer reviewers in 2020.   JAMA Oncol. Published online March 25, 2021. doi:10.1001/jamaoncol.2021.0146Google Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×